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Abstract
 
In contrast to protein antigens, processing of glycoproteins by dendritic cells (DCs) for presen-
tation to T cells has not been well studied. We developed mouse T cell hybridomas to study
processing and presentation of the tumor antigen MUC1 as a model glycoprotein. MUC1 is
expressed on the surface as well as secreted by human adenocarcinomas. Circulating soluble
MUC1 is available for uptake, processing, and presentation by DCs in vivo and better under-
standing of how that process functions in the case of glycosylated antigens may shed light on
antitumor immune responses that could be initiated against this glycoprotein. We show that
DCs endocytose MUC1 glycopeptides, transport them to acidic compartments, process them
into smaller peptides, and present them on major histocompatability complex (MHC) class II
molecules without removing the carbohydrates. Glycopeptides that are presented on DCs are
recognized by T cells. This suggests that a much broader repertoire of T cells could be elicited
against MUC1 and other glycoproteins than expected based only on their peptide sequences.
Key words: antigen presenting cells • endocytosis • peptide epitopes • glycoepitopes • T cell 
hybridomas
 
Introduction
 
CD8
 
 
 
 and CD4
 
 
 
 T cells recognize protein antigens pre-
sented as peptides bound to MHC class I and II molecules
(1, 2). Generation of class II–restricted peptide epitopes
by APCs follows a multistep process (for a review, see ref-
erence 3). Upon entering the cell through endocytosis,
the antigen is transported in endocytic vesicles to process-
ing compartments where it undergoes proteolytic cleav-
ages by specialized enzymes (4). The resulting peptides
bind to MHC class II molecules residing in these com-
partments and are transported to the cell surface for pre-
sentation to CD4
 
 
 
 T cells (5). Various aspects of this
pathway have been elucidated using as model antigens
unglycosylated proteins that yield unglycosylated peptides
for recognition by MHC class II–restricted T cells (6, 7).
As a result, our understanding of processing of complex
glycoproteins is much less advanced, even though many
protein antigens that are encountered by the APC are gly-
cosylated. Protein glycosylation is a posttranslational mod-
ification that can have great impact on immunogenic
properties of many antigens (8, 9). Many viral envelope
proteins are glycoproteins that use this biochemical char-
acteristic to avoid immune detection (10, 11). In autoim-
mune diseases such as rheumatoid arthritis and systemic
lupus erythematosus, changes in IgG glycoforms contrib-
ute to the immunopathology of these diseases (12). Aller-
gens like the bee venom phospholipase A2 are glycopro-
teins and the carbohydrate structures are responsible for
their immunogenic properties (13). In tumor cells, dramatic
changes in protein glycosylation create tumor-specific glyco-
proteins that can be recognized by the immune system as
tumor-specific antigens (14). Type II collagen (15, 16),
bee venom allergen phospholipase A2 (13), and HIV en-
velope glycoprotein (17) are among the very few glyco-
sylated antigens studied to date for their ability to generate
class II–restricted glycoepitopes. The basic question that
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has not yet been answered is whether sugars are removed
during antigen processing.
We have addressed the fate of sugars on glycoprotein an-
tigens by studying the mucin-like glycoprotein MUC1.
MUC1 is a human tumor antigen expressed in a variety of
adenocarcinomas. MUC1 made by normal cells is highly
glycosylated with branched 
 
O
 
-linked oligosaccharides (18).
By contrast, in tumor cells, MUC1 
 
O
 
-glycosylation is
prematurely terminated, leading to the accumulation of
short carbohydrate precursors such as monosaccharide Tn
(GalNAc
 
 
 
1-O-S/T) or disaccharide T (Gal
 
 
 
1–3GalNAc
 
 
 
1-
O-S/T), and their sialylated forms sTn and sT, respectively
(for a review, see reference 19). These tumor-specific car-
bohydrates are 
 
O
 
-linked to serines and threonines in the
tandem repeat domain of the MUC1 molecule that consists
of a variable number of 20 amino acid–long repeats. Each
tandem repeat (HGVTSAPDTRPAPGSTAPPA) has five
glycosylation sites, three threonines and two serines (for a
review, see reference 20).
Our results obtained with MUC1-specific T hybridomas
show that dendritic cells (DCs)
 
*
 
 process and present
MUC1 glycopeptides without removing the 
 
O
 
-linked car-
bohydrates. Thus, in addition to peptide epitopes that are
presented to CD4
 
 
 
 Th cells, there exist glycopeptide
epitopes that are presented and could trigger a completely
different repertoire of glycopeptide-specific T cells. In the
case of MUC1, which has the same protein sequence in
normal and tumor cells but different glycosylation profile,
the peptide epitopes are shared between normal and tumor
cells, but the glycopeptide epitopes are expected to be tu-
mor specific. Thus, the knowledge that these epitopes are
presented and can potentially be tumor-specific targets for
glycopeptide-specific T cells may be critically important for
tumor-specific immunotherapy.
 
Materials and Methods
 
Animals.
 
6–8-wk old C57BL/6 female mice used for immu-
nizations were purchased from The Jackson Laboratory and
housed at the University of Pittsburgh Cancer Institute (Pitts-
burgh, PA) Animal Facility. All experiments were approved by
the IACUC of the University of Pittsburgh.
 
Chemical and Enzymatic Synthesis of MUC1 Peptides and Glyco-
peptides.
 
The 140mer and the 100mer peptides represent 7 and
5 repeats of a 20 amino acid sequence HGVTSAPDTRPAPG-
STAPPA from the MUC1 tandem repeat region. These two
peptides and the 13mer (HGVTSAPDTRPAP) and 9mer
(HGVTSAPDT) were synthesized on a Chemtech 200 machine
with 
 
N
 
-(9-fluorenyl) methoxycarbonyl chemistry and purified by
HPLC in the University of Pittsburgh Cancer Institute peptide
synthesis facility.
Glycopeptides A1 to A7, and A13 were synthesized at the In-
stitute of Organic Chemistry, University of Hamburg, and char-
acterized at the Institute of Biochemistry II, University of Co-
logne, as described previously (21). Identical protocols were used
for the synthesis of H1 and H2. Crude preparations of the glyco-
 
peptides were chromatographed on PLRP-S reversed-phase col-
umns (250 
 
 
 
 4.6 mm, Polymer Laboratories) on a preparative
scale and the eluted fractions analyzed for purity by MALDI mass
spectrometry on a Bruker-Reflex III as described previously (22).
The GalNAc-100mer (Tn100mer) was prepared by enzymatic
addition of GalNAc to a synthetic peptide substrate using recom-
binant UDP-GalNAc:polypeptide 
 
N
 
-acetyl-galactosaminyltrans-
ferases rGalNAc-T1 and -T2 (provided by H. Clausen, School of
Dentistry, University of Copenhagen, Denmark) under condi-
tions described previously (22). The reaction mixtures were incu-
bated at 37
 
 
 
C for up to 72 h with additions of cosubstrate and
fresh enzyme at 24-h intervals. The reaction was monitored by
matrix-assisted laser desorption/ionization (MALDI) mass spec-
trometric analysis. The final reaction product contained a total
number of 15 GalNAc residues per 100mer peptide that were in-
corporated within threonine in VTSA region and adjoining
serine and threonine within GSTA region, consistent with the
site-specificity of the rGalNAc-Ts used (22).
The T100mer glycopeptide was synthesized from the Tn-
100mer which was converted into the corresponding T-100mer
by addition of galactose using a recombinantly expressed core1-
Gal-transferase from 
 
Drosophila melanogaster
 
 (provided by T.
Schwientek, Institute of Biochemistry, University of Cologne,
Cologne, Germany). 
 
 
 
2 mg of Tn-100mer was incubated in 1
ml of reaction buffer (100 mM MES, pH 6.5, 0.1% Triton X-100,
20 mM MnCl2, 20 mM DTT) containing 4 mM UDP-Gal and
0.5–1 mU of enzyme. Fresh cosubstrate and enzyme were added
after 24 h and the reaction was stopped after 48 h. The products
were separated by reversed phase chromatography on a PLRP-s
column. According to mass spectrometry the major products
contained 8–10 Gal residues per 100mer.
MCF-7 and T47D glycoforms were described previously (23).
They were obtained by transfection of MCF-7 and T47D breast
cancer cell lines with a vector encoding the fusion protein con-
taining six tandem repeats of MUC1. The mammalian episomal
expression vector pCEP-PU contains the signal peptide of the
BM40 extracellular matrix protein, followed by a hexa-histidine
sequence and a myc tag. Protein expression is driven by the cy-
tomegalovirus promoter. The quality of the preparations was an-
alyzed by SDS-PAGE followed by blotting onto nitrocellulose
membranes and the fusion proteins were detected with an anti-
myc mAb (Santa Cruz Biotechnology, Inc.).
The unmodified 19-mer (HGVTSAPDTRPAPGSTAPP)
MUC1 peptide and the corresponding glycosylated analogs (W2-
W7) were synthesized at The Wistar Institute by conventional
solid-phase methods. The assembly was made on a Rainin PS3
automated synthesizer on TentaGel S-Ram-Fmoc resin with an
initial load of 0.3 mmol/g (Advanced ChemTech). Standard
Fmoc chemistry was used throughout (24) with four molar excess
of the acylating amino acids and HATU (1-hydroxy-7-azabenzo-
triazole uronium salt) activation, recommended for the synthesis
of complex peptides (25). FmocSer/Thr(maltoseGalNAc/malto-
hexoseGalNAc 
 
 
 
1;O)-OPfp (26) glycoamino acids were incor-
porated in the same manner as the unmodified amino acids, ex-
cept that they were coupled in 1.5 molar excess (to reduce
glycoamino acid usage) in the presence of di-isopropyl-ethyl-
amine (DIPEA).
 On completion of the assembly of the peptide chain, the
Fmoc protection on the NH
 
2
 
-terminal amino acid was retained.
Still polymer-bound, the azido group on the sugar ring was trans-
formed into an acetamido group using thioacetic acid for 4 d
with consecutive changes of the reagent (27). After reducing the
azido group, the Fmoc protection on the NH
 
2
 
-terminal amino
 
*
 
Abbreviations used in this paper:
 
 DC, dendritic cell; EAE, experimental au-
toimmune encephalomyelitis; MIIC, MHC class II-rich compartment. 
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acid was removed using 20% piperidine in dimethyl formamide.
The resulting glycopeptides, as well as the unmodified 19-mer
peptide were cleaved from the solid support with trifluoroacetic
acid in the presence of thioanisol (5%), and water (5%) as scaven-
gers for 2 h. Deacetylation of the sugar hydroxyl group was ac-
complished by treatment with 0.1 M NaOH (28). Reaction time
of 10 min was sufficient for the peptides containing trisaccharide,
and 20 min was needed for those carrying heptasaccharide side-
chains. After cleavage, the peptides were purified by RP-HPLC
(preparative runs: isocratic elution of 5% solvent B for 5 min fol-
lowed by a linear gradient from 5 to 65% solvent B for 300 min).
The final products were characterized by RP-HPLC (during the
analytical runs the same gradient was developed over a 45-min
period) and MALDI-MS.
All peptides are listed in Table I.
 
Generation of DCs. 
 
DCs were generated as described previ-
ously (29), from bone marrow precursors (C57Bl/6 mice) in the
presence of 10 ng/ml murine GM-CSF and 10 ng/ml IL-4 (gifts
from Immunex). DCs were purified after 5 d in culture, using a
Nycoprep gradient (Nycomed). This protocol produces pheno-
typically immature DCs (30).
 
Generation of T Cell Hybridomas.
 
For peptide-specific hybrid-
omas, purified immature DCs were loaded overnight at 37
 
 
 
C,
with 20 
 
 
 
g/ml of 140-mer MUC1 peptide. Additional soluble
140-mer MUC1 peptide was added to the preloaded DCs at a fi-
nal concentration of 100 
 
 
 
g per mouse, right before vaccination.
C5BL/6 mice were immunized with 5 
 
 
 
 10
 
5
 
 DCs per mouse
subcutaneously in the right hind flank and boosted twice at 3-wk
intervals. 10 d after the last boost, inguinal lymph nodes and
spleen lymphocytes were pooled and plated in 6-well plates (Bec-
ton Dickinson) at two million cells/ml in complete DMEM-10
medium (ICN) and restimulated with soluble 140-mer peptide
(20 
 
 
 
g/ml). After 36 h of culture, the cells were fused in the
presence of polyethylene glycol (Sigma-Aldrich) with the
BW5147 TCR 
 
 
 
 
 
 
 
 
 
 lymphoma cell line (American Type Cul-
ture Collection), according to published protocols (31, 32). Fused
cells were monitored for 2–3 wk and cells showing growth were
tested for CD3 and CD4 expression by FACS
 
®
 
 (antibodies pur-
chased from BD PharMingen). The CD3
 
 
 
 hybridomas were
screened for antigen recognition using an ELISA-based IL-2 de-
tection protocol. Antigen-specific hybridomas were subcloned by
limiting dilution.
For glycopeptide-specific hybridomas, inguinal and mesen-
teric lymph nodes and spleens from C57Bl/6 mice were har-
vested and lymphocytes primed in vitro with DCs loaded over-
night (as described above) with pooled A2-A7 (see Table I)
MUC1 21mer glycopeptides (20 
 
 
 
g/ml each). Every 7 d, T cell
cultures were restimulated with overnight-loaded DCs. 3 d after
the third restimulation, viable T cells were fused with BW5147
lymphoma cells as described above. The same phenotypic (CD3,
CD4 expression) and functional screening (IL-2 release in re-
sponse to the antigen) was performed as with the peptide-specific
T hybridomas.
 
Antigen Specificity and IL-2 Detection by ELISA.
 
DCs were
loaded with antigen (20 
 
 
 
g/ml, unless otherwise indicated) for
16 h.
Equal amounts (in 
 
 
 
g/ml) of all short and long peptides and
glycopeptides were assayed rather than equimolar quantities be-
cause the 100mer comprises five tandem repeats/molecule, each
repeat generating one epitope (up to five epitopes per molecule)
upon processing by DCs.
Antigen-loaded and control, no antigen DCs were added at
10
 
4
 
 cells per well (unless otherwise indicated) to Immulon 4
 
ELISA plates (Dynex Technologies Inc.), in triplicates. The T
hybridoma cells were added at a density of 10
 
5
 
 cells per 100 
 
 
 
l
per well, for 24 h. 100 
 
 
 
l of the supernatant was tested for the
presence of IL-2 by ELISA, using IL-2 detection kit (BD Phar-
Mingen). ELISA plates were read in an automatic ELISA reader,
using MRX Revelation software (Dynex Technologies). Data
was plotted using Cricket graph software.
 
Confocal Laser Scanning Microscopy.
 
MUC1 peptides and gly-
copeptides were directly conjugated to either Cy3 or Cy5 fluo-
rescent dyes according to manufacturer’s protocol (Amersham
Pharmacia Biotech). Free dye was separated from the conjugated
protein by mass chromatography and the final concentration of
protein determined in collected fractions using a protein assay kit
(Bio-Rad Laboratories).
Day 5 immature DCs were resuspended in polypropylene
tubes at 5 
 
 
 
 10
 
4
 
 cells per 250 
 
 
 
l of AIM V DC medium and ex-
ogenously pulsed with 20 
 
 
 
g/ml fluorescently labeled peptides
for 2 h. For the last 30 min of incubation, DCs were pulsed
with 5 
 
 
 
M of green fluorescent BODIPY FL Pepstatin A (Mo-
lecular Probes). After uptake and processing, DCs were briefly
fixed in 2% paraformaldehyde, washed in serum-containing me-
dium and indirectly stained for intracellular and/or cell surface
MHC class II. Staining with primary anti–mouse IA
 
b
 
 antibody
(BD PharMingen) was followed by secondary Alexa 488, Alexa
546, or Cy5-labeled (Molecular Probes) antibodies. When in-
tracellular staining was employed, the antibody was diluted in
0.1% Triton X-100.
The final concentration of antibodies used for staining was 5
 
 
 
g/ml. After staining, DCs were mounted on glass slides and im-
mediately analyzed by confocal laser microscopy at the University
of Pittsburgh Center for Biological Imaging Facility, using a Leica
TCS NT confocal LSM microscope. Images were collected using
the 
 
 
 
100 objective, as serial sections. Individual sections are pre-
sented (of generally 4–8 cells collected). Cy5 is a far-red fluores-
cent dye to which we have assigned the color blue.
 
Antigen Processing Assay.
 
Day 5 immature DCs were either
fixed in 1% paraformaldehyde for 10 min at room temperature or
pretreated for 30 min at 37
 
 
 
C with either of the following inhib-
itors (all from Sigma-Aldrich): 2 mM sodium azide; 2 deoxyglu-
cose (100 
 
 
 
M); or a protease inhibitors cocktail 25- or 100-fold
diluted (concentration of some of the protease inhibitors in the
stock solution are 100 
 
 
 
g/ml aprotinin; 500 
 
 
 
M leupeptin; 500
 
 
 
M E-64; 50 mM AEBSF; and 100 mM EDTA). Cells were ex-
tensively washed upon treatment and then resuspended in
polypropylene tubes (Becton Dickinson) in 200 
 
 
 
l final volume
of AIM V serum-free medium. Viability of DCs was assessed be-
fore and after pretreatment by Trypan Blue (GIBCO BRL) ex-
clusion method. Control DCs were treated with DMSO only
(used as a vehicle for protein inhibitors; Sigma-Aldrich). Syn-
thetic peptides were then added at 20 
 
 
 
g/ml and DCs incubated
at 37
 
 
 
C (or on ice, in inhibition experiments) in a humidified
CO
 
2
 
 incubator for 16 h (unless otherwise stated). DCs were
plated in 96-well plates at a density of 10
 
4
 
 cells per well and T
hybridomas added at a density of 10
 
5
 
 cells per well. Experiments
were performed in triplicate and at least on two occasions.
 
Detection of Processed MUC1 Peptides and Glycopeptides on the
Surface of DCs by FACS
 
®
 
.
 
DCs were loaded as above, washed,
fixed, and stained for 30 min at 4
 
 
 
C, in the dark. Staining was
performed either directly using FITC-labeled Vicia villosa lectin
(EY Laboratories) or indirectly with anti-MUC1 monoclonal an-
tibodies VU-4-H5, VU-3-C6 (33) and BCP9 followed by AL-
EXA 488 anti–mouse secondary antibody (Molecular Probes).
Surface staining of DCs with the fluorescent lectin was performed 
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on DCs pulsed with the antigen either post- or prior fixation in
1% PFA for 10 min at room temperature. Fixed cells were exten-
sively washed upon fixation. Stained cells were immediately ana-
lyzed with a Becton Dickinson FACScalibur™ and data analyzed
with CELLQuest™ software.
 
Results
 
MUC1 Peptide Specificity and MHC Class II Restriction of
the CD4
 
 
 
 T Hybridoma VF5.
 
MUC1 peptide-specific T
hybridomas were generated after an in vivo DCs based im-
munization protocol, and screened for specificity by coin-
cubation with immature bone marrow–derived DCs exog-
enously loaded for 16 h with the synthetic MUC1 100mer
peptide. The 100mer peptide (Table I) represents five 20
amino acids-long repeats from the MUC1 tandem repeat
region. The supernatants of these cocultures were tested for
the presence of IL-2 by ELISA and compared with super-
natants from cocultures with control DCs that did not
receive antigen. We identified one stable MUC1 peptide-
specific T cell hybridoma (clone VF5). CD3 and CD4 ex-
pression by this T cell clone are shown in Fig. 1, A and B.
This clone produced IL-2 in response to DCs loaded with
MUC1 100mer peptide and not in response to control
DCs. The response was dose-dependent and varied accord-
ing to various T/DC ratios and various peptide concentra-
tions (Fig. 1, C and D). Monoclonality was achieved
through multiple subclonings by limiting dilution, and
confirmed by PCR analysis of the TCR genes (unpub-
lished data).
MHC class II restriction of clone VF5 was confirmed us-
ing DCs generated from B6.NOD mice (H-2
 
g7
 
) mis-
matched in MHC class II with C57BL6 mice (I-A
 
b
 
). Fig. 1
E shows that clone VF5 produces IL-2 in response to the
100mer peptide only when presented by the C57BL6 DC
(I-A
 
b
 
) and not by B6.NOD DC (I-A
 
g7
 
). The B6.NOD
DCs can otherwise function well as APC, demonstrated by
their ability in the same experiment to stimulate a class I
(H-2
 
b
 
) restricted T hybridoma specific for the 8mer (SIIN-
FEKL) OVA peptide (unpublished data).
Long peptides, such as the MUC1 100mer, exogenously
administered to DCs are expected to be enzymatically
cleaved into 13–25 amino acid long epitopes that are then
presented on MHC class II molecules on the cell surface
(3). Consistent with that, IL-2 secretion by clone VF5 was
also detected in response to a 19mer peptide HGVTSAP-
DTRPAPGSTAPP (Fig. 1 F). By testing even shorter pep-
tides, we determined that the minimal epitope recognized
by VF5 hybridoma resides within the 13mer HGVTSAP-
DTRPAP sequence. Further truncation to a 9mer peptide
HGVTSAPDT abrogates the response presumably because
this peptide is too short to bind to I-A
 
b
 
.
 
The Long and the Short MUC1 Peptides Are Internalized by
DCs and Trafficked to Endocytic Vesicles.
 
We fluorescently
labeled the 100mer, 19mer, and 13mer peptides with Cy3
 
Table I.
 
MUC1 Peptides and Glycopeptides
 
Peptide Sequence and glycosylation sites
 
a
 
Carbohydrate type and length
100mer  (GVTSAPDTRPAPGSTAPPAH)
 
   
 
5 None
19mer HGVTSAPDTRPAPGSTAPP None
13mer HGVTSAPDTRPAP None
9mer HGVTSAPDT None
Tn-100mer (GV
 
T
 
SAPDTRPAPG
 
ST
 
APPAH) 
 
  
 
5 GalNAc(
 
 
 
1-O)
H1 AHGV
 
T
 
SAPDTRPAPGSTAPPA GalNAc(
 
 
 
1-O)
H2 AHGVTSAPDTRPAPGS
 
T
 
APPA GalNAc(
 
 
 
1-O)
A13 AHGVTSAPD
 
T
 
RPAPGSTAPPA GalNAc(
 
 
 
1-O)
A1 AHGV
 
T
 
SAPDTRPAPGSTAPPA Gal(
 
 
 
1-3)-GalNAc(
 
 
 
1-O)
A2 AHGVTSAPD
 
T
 
RPAPGSTAPPA Gal(
 
 
 
1-3)-GalNAc(
 
 
 
1-O)
A3 AHGVTSAPDTRPAPGS
 
T
 
APPA Gal(
 
 
 
1-3)-GalNAc(
 
 
 
1-O)
A4 AHGVT
 
S
 
APDTRPAPGSTAPPA Gal(
 
 
 
1-3)-GalNAc(
 
 1-O)
A5 AHGVTSAPDTRPAPGSTAPPA Gal( 1-3)-GalNAc( 1-O)
A6 AHGVTSAPDTRPAPGSTAPPA Gal( 1-3)-GalNAc( 1-O)
A7 AHGVTSAPDTRPAPGSTAPPA Gal( 1-3)-GalNAc( 1-O)
W2 HGVTSAPDTRPAPGSTAPP Glc( 1-4)-Glc( 1-4)-GalNAc( 1-O)
W3 HGVTSAPDTRPAPGSTAPP Glc( 1-4)-Glc( 1-4)-GalNAc( 1-O)
W4 HGVTSAPDTRPAPGSTAPP Glc( 1-4)-Glc( 1-4)-GalNAc( 1-O)
W6 HGVTSAPDTRPAPGSTAPP [Glc( 1-4)-Glc] 3-GalNAc( 1-O)
W7 HGVTSAPDTRPAPGSTAPP [Glc( 1-4)-Glc] 3-GalNAc( 1-O)
aGlycosylated threonine (T) and serine (S) residues are marked in bold.1439 Vlad et al.
(a red fluorescent dye) and by confocal scanning micros-
copy tracked their presence inside DCs after a 2-h loading
period. DCs were stained for class II on the surface using a
green fluorescent antibody. Fig. 2 demonstrates intense ac-
cumulation of the 100mer (Fig. 2 A), 19mer (Fig. 2 B),
and 13mer (Fig. 2 C) peptides inside (rather than on the
surface of) DCs. The discrete, vesicular staining of inter-
nalized fluorescent peptides suggests endosome-like struc-
tures. Further proof that these vesicles are intracellular was
obtained by consecutive scanning sections through cells,
and one such example is shown for the 13mer peptide in
panels D–I.
MUC1 Glycopeptides Are Not Deglycosylated during Process-
ing by DCs. We synthesized a 100mer MUC1 peptide
with a monosaccharide GalNAc linked to at least three out
of five (two serines and three threonines) O-glycosylation
sites within each tandem repeat (Tn-100mer, Table I). We
also synthesized a series of 19mer and 21mer peptides with
specific threonines and serines glycosylated with mono-,
di-, tetra-, or heptasaccharides (shown in Table I). These
glycopeptides were designed to represent different forms of
MUC1 produced by tumor cells. We analyzed the ability
of the peptide-specific hybridoma VF5 to recognize
epitopes derived after processing of these glycopeptides by
DC (Fig. 3). Unglycosylated peptides, 100mer and 19mer
served as positive controls. In Fig. 3 A, we see that com-
pared with the DCs loaded with the unglycosylated
100mer, which was recognized very well, there was no
recognition of DCs loaded with the glycosylated Tn-
100mer. Yet Tn-100mer was also endocytosed (Fig. 3 D,
blue) when fed to DCs simultaneously with the 100mer
(red) and colocalized with it in endocytic compartments
(Fig. 3 E, purple). It also colocalizes (yellow) with I-Ab
(green) in intracellular MHC class II–rich compartments
(Fig. 3 F). In Fig. 3 A we also see that the hybridoma was
able to secrete IL-2 in response to an epitope derived from
the monosaccharide-substituted glycopeptide H2, glycosyl-
ated on the third threonine (counting from the NH2 termi-
Figure 1. Phenotypic and functional characterization of MUC1 pep-
tide-specific T hybridoma VF5. Flow cytometric analysis was performed
for CD3 (A) and CD4 (B) expression. Cells were incubated in the pres-
ence of either FITC-labeled isotype control antibody (thin line) or anti-
CD3 or anti–CD4-FITC (thick line) antibodies. Antigen specificity was
assessed in IL-2 detection assay, by ELISA (C and D). Day 5 bone marrow–
derived DCs were loaded with 40  g/ml 100mer MUC1 peptide and co-
incubated with VF5 T cells at various DC/T cell ratios (x axis), in tripli-
cate, for 24 h (C). DCs were loaded for 16 h with various concentrations
of 100mer peptide (in  g/ml, on the x axis) and added to VF5 T cells at a
1:10 ratio (D). VF5 cells were coincubated (1:10 DC/T cell ratio) with
either syngenic DCs from C57Bl/6 (I-Ab) mice or with allogeneic DCs
from B6.NOD mice (I-Ag7) mice, pulsed with 20  g/ml antigen as de-
scribed above (E). DCs were loaded with 20  g/ml of 100mer, 19mer,
13mer, and 9mer MUC1 peptides, in triplicates, for 16 h and then added
to VF5 cells at a 1:10 ratio (F). After 24 h of coculture, the supernatant
was tested for IL-2 by ELISA (C–F). Results represent means of optical
density units. Every assay had an IL-2 standard curve included. IL-2 pro-
duction by T cells in the presence of antigen-loaded DCs was compared
with IL-2 production in the presence of control DCs and statistical signif-
icance determined using Student’s t test (P   0.005).
Figure 2. Intracellular localization of MUC1 synthetic peptides after
endocytosis by DCs. DCs were exogenously loaded with Cy 3 (red)-
labeled 100mer (A), 19mer (B), and 13mer (C) peptides for 2 h, washed,
fixed, and counterstained green for cell surface IAb and analyzed with
confocal laser microscopy. Panel C represents one section from a series of
16 0.5- m thick sections taken through a cell pulsed with 13mer peptide,
six of which are shown in panels D-I. All images were acquired at  100
original magnification.1440 Carbohydrates Are Not Removed during Antigen Processing
nus of the peptide), but not in response to epitopes derived
from glycopeptide H1, glycosylated on the first threonine,
or glycopeptide A13, glycosylated on the second threonine.
We concluded that the glycosylation of the first two threo-
nines interfered with the recognition of the peptide epitope
by the hybridoma, suggesting that the sugars were not re-
moved during processing.
When DCs were fed 21mer peptides (Table I) bearing
disaccharide Gal-GalNAc linked to individual serines and/
or threonines (known as the tumor-specific T antigen),
similar pattern of responses from the T hybridoma was seen
(Fig. 3 B). Glycosylation on the second threonine (glyco-
peptide A2) and first serine (glycopeptide A4) interfered
with the epitope recognition by the hybridoma, while the
presence of the disaccharide at the COOH-terminal threo-
nine did not (glycopeptide A3). Glycosylation of the serine
in the COOH-terminal sequence GSTAPPA also did not
interfere with the recognition by T cells (unpublished data),
which may suggest that it is cleaved during processing.
Similar results were obtained from experiments with
peptides bearing elongated sugars (trisaccharide-peptides
W2, W3, and W4, or heptasaccharide-peptides W6 and
W7, Table I). These glycopeptides were tested under the
hypothesis that longer sugar chains might be handled dif-
ferently by the DC antigen processing compartments.
What we found was that regardless of the sugar chain
length, the same pattern of epitope recognition was de-
tected: sugars within the minimal HGVTSAPDTRPAP
epitope interfered with the hybridoma recognition while
sugars within the GSTAPPA COOH-terminal sequence
did not (Fig. 3 C).
Recognition of MUC1 Peptides and Glycopeptides Requires
Active Uptake and Transport to Acidic, Enzyme-rich Endocytic
Compartments. While complex protein antigens and long
synthetic peptides are expected to require intracellular
processing before their presentation on MHC class II,
small peptides derived from some antigens (but not others)
could directly bind to cell surface MHC class II molecules
(34–36) and be presented equally well by fixed and non-
fixed APCs (37, 38). We showed earlier in Fig. 2 that
MUC1 peptides, regardless of their length, are endocy-
tosed by DCs. In Fig. 4 A we confirm that metabolically
active DCs are required for MUC1 processing and presen-
tation to the VF5 hybridoma since DCs fixed before the
addition of peptides are not able to elicit a response. Fixing
cells after incubation with the peptides did not affect pep-
tide presentation, suggesting that the ability of the DCs to
successfully activate T hybridomas was preserved. Simi-
larly, DCs pulsed on ice or pretreated with sodium azide/2
deoxyglucose before antigen pulse to disrupt active en-
docytosis (34), generated significantly lower IL-2 responses
(Fig. 4 B) suggesting that endocytosis is necessary for VF5
epitope presentation.
Also, we wanted to see if both, the long and the short
peptides, once internalized, were subjected to proteolytic
cleavage into smaller fragments. Our assumption was that
this would be required for the long peptide, the MUC1
100mer, but that the shorter peptides may or may not be
further trimmed. Intracellular processing compartments in
DCs are rich in proteolytic enzymes. The most prominent
enzymes are cysteine proteases (such as Cathepsins B, H, L,
S, etc.), aspartic proteases (Cathepsins D and E), and aspar-
aginyl endopeptidase. We used a cocktail of chemical re-
agents that could specifically inhibit serine, cysteine, aspartic,
and metalloproteases. As seen in Fig. 4 C, we successfully
inhibited processing of the 100mer peptide but not of the
small peptides suggesting that even though they are longer
than average class II binding peptides they may still bind. If
cleavage of the COOH-terminal segment is blocked it is
not expected to interfere with the MHC-peptide-TCR
complex formation being outside the VF5 epitope.
To show that lack of inhibition seeing with the short
peptides is not due to their exclusion from the antigen pro-
cessing compartments, we used confocal microscopy to
Figure 3. Selective recognition by peptide-specific
clone VF5 of DC loaded with different glycopeptides. DCs
were loaded with indicated MUC1 peptides and glycopep-
tides at 20  g/ml for 16 h, then coincubated with VF5
cells at 1:10 ratio, for 24 h. Culture supernatants were
assayed for IL-2 presence by ELISA as described above.
(A) DCs were loaded with 100mer and 21mer peptides
modified with tumor-like monosaccharide Tn (GalNAc)
antigen. (B) DCs were loaded with peptides modified with
tumor-like disaccharide T (Gal-GalNAc) antigen. (C) DCs
were loaded with trisaccharide glycopeptides (W2, W3,
and W4) or heptasaccharide glycopeptides (W6 and W7).
Precise sites of glycosylation of all glycopeptides can be
found in Table I. Results are represented as means of optical density units.
(D and E) Confocal micrographs of DCs (stained green for cell surface
MHC class II) exogenously pulsed with Cy5-labeled (blue) Tn100mer
antigen alone (D) or together with Cy3–100mer (red) MUC1 peptide (E)
for 2 h. Colocalization of peptide and glycopeptide in vesicular compart-
ments (purple) marked with arrows. (F) Colocalization (in yellow) of
Tn-100mer peptide (red) with I-Ab (green) in DCs stained, after 2-h an-
tigen pulse, for cell surface and intracellular MHC class II. Images are sin-
gle scanned sections acquired at original magnification:  100.1441 Vlad et al.
colocalize Cy3 labeled MUC1 peptides (red) with other
molecules that reside in the endosomes. Green fluorescent
pepstatin A is a marker for endocytic compartments (39).
Pepstatin A is internalized through an endocytic pathway
and transported to lysosomes where it binds cathepsin D,
one of the major endopeptidases involved in protein degra-
dation. We show that it colocalizes with the 100mer (Fig. 4
D), 19mer (Fig. 4 E), and 13mer (Fig. 4 F) peptides. An-
other marker of the intracellular processing compartments
of the endocytic pathway is MHC class II. Trafficking of
the 100mer peptide to MHC class II-rich compartments
(MIIC) has been reported previously (40). Here we show
that the 19mer peptide (red, Fig. 4 H) and intracellular I-Ab
(green, Fig. 4 G), colocalize in the same vesicles (Fig. 4 I),
confirming trafficking of the small MUC1 peptides to ve-
sicular, enzyme-rich MIIC compartments.
MUC1-derived Glycoepitopes Are Presented on the DC Cell
Surface. We interpreted the lack of reactivity of the VF5
hybridoma with some of the glycopeptides to be due to
the persistence of sugars in the epitope after processing.
However, an alternative possibility is that glycosylation
could interfere with the processing or binding of glyco-
peptides to MHC class II molecules and therefore they
may not be presented. To rule out this latter possibility we
confirmed the presence on the DC cell surface of pro-
cessed MUC1 glycoepitopes derived from the longest gly-
copeptide, the Tn-100mer. We stained DCs loaded with
the Tn-100mer with anti-MUC1 antibodies that specifi-
cally recognize defined epitopes within a MUC1 tandem
repeat. mAbs that recognize peptides bound to MHC class
II molecules are rare (41). Several anti-MUC1 antibodies
have been reported to recognize both the native MUC1 as
well as MUC1 peptides in MHC (42). DCs pulsed with
Tn-100mer were washed, fixed, and then stained with
anti-MUC1 mAbs VU-4-H5 (Fig. 5 A), VU-3-C6 (Fig. 5
B), and BCP9 (Fig. 5 C). VU-4-H5 and VU-3-C6 recog-
nize overlapping epitopes (33) within the DTRPAP se-
quence that are in the epitope recognized by the VF5
hybridoma. Glycosylation of these epitopes does not in-
terfere with their recognition by the antibodies. The
epitope recognized by antibody BCP9 (PAPGSTAP) lies
in the COOH-terminal region of the MUC1 tandem re-
peat (43). This is also the region where glycosylation of
serine and threonine residues does not interfere with the
recognition of the VF5 epitope, suggesting that it is
cleaved during glycopeptide processing. VU-3C6 and
VU-4H5 react with their epitopes while BCP9 does not.
If the Tn-100mer was merely bound on the surface of the
DCs, all three antibodies would show positive staining.
The lack of staining with BCP9 indicates that during pro-
cessing of the Tn-100mer its epitope is destroyed while
the epitopes recognized by the other two antibodies are
preserved. Thus, even though the peptide specific clone
VF5 does not “see” these epitopes, they are nevertheless
processed and presented on DCs.
To confirm that monosaccharide residues are still at-
tached to the processed MUC1 peptide epitopes presented
on the cell surface, we stained the same Tn-100mer-loaded
Figure 4. Inhibition of uptake and processing in endocytic compart-
ments of both long and short MUC1 peptides and glycopeptides. DCs
were either briefly fixed in 1% PFA (A, white bars), pretreated with 2
mM sodium azide/100  M 2 deoxyglucose (B, white bars) or with a
protease inhibitors cocktail (C) 100-fold (white bars) or 25-fold diluted
(gray bars), 30 min before addition of 20  g/ml MUC1 peptides and gly-
copeptides. No inhibitor was added to control DCs (black bars in A–C).
In panel B, DCs were pulsed with antigen on ice (gray bars). In panel C,
hatched bars represent DMSO control treated DCs. After 6 h of pulse,
treated and untreated DCs were incubated with the VF5 cells and IL-2
was measured by ELISA. (D–F) Confocal micrographs of DCs exoge-
nously pulsed with Cy3-labeled (red) 100mer (D), 19mer (E), and 13mer
(F) MUC1 peptides for 2 h. During the last 30 min of the pulse period,
DCs were also fed BODIPY FL Pepstatin A (green). Surface staining for
MHC class II is shown in blue. Overlay sections show area of red-green
colocalization (yellow) marked with arrows. (G–I). Confocal micrograph
of DCs pulsed with Cy5-labeled 19mer peptide for 2 h and stained after
the pulse for extracellular and intracellular I-Ab (green, G). Colocalization
of antigen (red, H) and MHC class II in yellow (I).1442 Carbohydrates Are Not Removed during Antigen Processing
DCs with FITC-labeled lectin Vicia villosa that specifically
binds GalNAc (Tn antigen). Histograms in Fig. 5 D show
positive staining of the Tn-100mer-loaded DCs compared
with control DCs. To rule out staining of unprocessed Tn-
100mer nonspecifically bound to the DC surface, we used
as an additional control Tn-100mer-loaded fixed DCs un-
able to endocytose antigens (Fig. 5 E).
Processed Glycopeptides Are Recognized by a Glycopeptide-
specific T Hybridoma. Presentation of glycosylated MUC1
epitopes by DCs is most conclusively demonstrated by their
recognition by T cells. We generated T cell hybridomas by
in vitro priming and restimulation of T lymphocytes with
DCs loaded with pooled disaccharide-substituted glycopep-
tides. We isolated one hybridoma, VF9, that showed speci-
ficity for DCs loaded with the pooled priming glycopep-
tides A2-A7 and did not react with DCs loaded with
unglycosylated 19mer and 13mer (Fig. 6 A). The response
of VF9 hybridoma to DCs loaded with the individual gly-
copeptides (Fig. 6 B) shows specificity for two glycopep-
tides (A1 and A6), which have in common a disaccharide
(T antigen) attached to the first threonine (T1). This
hybridoma does not recognize the monosaccharide-substi-
tuted H1 glycopeptide or the corresponding unglycosylated
peptide (unpublished data), suggesting that presence of the
disaccharide is required. VF9 is CD3  (Fig. 6 C), CD4 
(Fig. 6 D) and I-Ab–restricted T hybridoma (Fig. 6 E).
Naturally Glycosylated Tumor MUC1 Is Processed by DCs to
Yield Peptide and Glycopeptide Epitopes Recognized by VF5
and VF9. Having one peptide-specific hybridoma that
recognizes a nonglycosylated epitope and a glycopeptide-
specific hybridoma that recognizes a tumor-specific glyco-
peptide bearing a Tn antigen, we could begin to explore
processing of MUC1 glycosylated in vivo by tumor cells
(Fig. 7). A gene construct encoding a six-tandem repeat
MUC1 fragment was expressed in MCF-7 and T47D
breast cancer cell lines. Complete O-glycan profiles of the
recombinant proteins purified from these cell lines have
been reported to represent the authentic glycosylation pat-
tern seen on MUC1 made by breast tumor cells (23).
While both cell lines produced underglycosylated tumor
MUC1 distinct from normal MUC1, the average density
of glycans per repeat was estimated to be 3 for MCF7 and
4.8 for T47D. We used these naturally glycosylated tumor
MUC1 preparations to investigate if their processing by
DCs would yield the peptide epitope recognized by the
VF5 hybridoma, or the glycopeptide epitope recognized by
Figure 5. Detection of processed MUC1 gly-
coepitopes on DC surface by antibody and lectin
staining. DCs were pulsed for 16 h with 20  g/ml
Tn-100mer MUC1 peptide and stained with anti-
MUC1 antibodies VU-4-H5 (A), VU-3-C6 (B)
and BCP9 (C). Epitopes recognized by each anti-
body are shown. Goat anti–mouse ALEXA 488
was used as a fluorescent secondary antibody. (D
and E) Staining with FITC-labeled Vicia villosa lec-
tin highly specific for Tn antigen. Thin line histo-
grams represent staining of control DCs, thick line
represents staining of Tn-100mer-loaded DCs (D).
DCs were loaded with Tn-100mer either prior
(thick line) or after (thin line) fixation in 1% PFA
for 10 min at room temperature (E).
Figure 6. Characterization of
VF9, a glycopeptide-specific T
hybridoma. DCs were loaded for
16 h with either pooled A2-A7
glycopeptides (20  g/ml each)
(A), or individual glycopeptides
(B). DCs were then coincubated
with VF9 cells for 24 h and su-
pernatants tested for IL-2 pres-
ence by ELISA, as described
above. (C and D) Flow cytomet-
ric analysis was performed for
CD3 (C) and CD4 (D) expression.
Cells were incubated in the presence of either FITC-labeled isotype con-
trol antibody (filled histograms) or anti-CD3 or anti-CD4-FITC antibod-
ies. (E) VF9 cells were coincubated (1:10 DC/T cell ratio) with either
syngeneic DCs from C57Bl/6 (I-Ab) mice or with allogeneic DCs from
B6.NOD mice (I-Ag7) mice, pulsed with 20  g/ml antigen, and IL-2
presence assayed by ELISA, as described above.1443 Vlad et al.
the VF9. The response of the VF5 hybridoma to DCs
loaded with MCF7-derived MUC1 was higher than to
DCs loaded with T47D-derived MUC1 (Fig. 7 A) consis-
tent with the higher probability of generating a nonglyco-
sylated peptide epitope from the MCF-7 glycoform with
fewer residues glycosylated.
These tumor forms of MUC1 also yielded VF9-specific
epitopes (Fig. 7 B), according to the expected density of T
antigens present in the respective preparations; MUC1 gly-
cosylated by MCF-7 cells has a 12.9% incidence of T anti-
gen as opposed to 6.9% on MUC1 produced by T47D
breast cancer cells (23). This difference is reflected in the
slightly higher amount of IL-2 released by VF9 hybridoma
in response to MCF-7–derived MUC1 compared with
T47D-derived MUC1. The efficiency of processing of
these natural glycoforms into VF9 epitopes is similar to the
efficiency of generation of this epitope from a synthetic
T-100mer MUC1 that has every Thr within the VTSA se-
quence glycosylated with the disaccharide T antigen.
Discussion
In attempting to understand immune responses to vari-
ous self- or foreign antigens, a lot of attention has been paid
to how they are processed by APCs and what sort of
epitopes are presented to T cells. Most of these studies to
date have focused on the protein sequence of specific anti-
gens and the peptide epitopes recognized by MHC class I–
or class II–restricted T cells. In many instances, though, the
native molecular forms available to DCs for uptake, pro-
cessing, and presentation are glycosylated or otherwise
posttranslationally modified. Recent findings that MHC
class II and I molecules can bind and present glycoepitopes
to CD4  (13, 15, 16) and CD8  T cells (44–48), predicts
that the immune repertoire will be broader than initially
thought. In fact, studies on autoimmune response have
provided useful insights on the repertoire of posttransla-
tionally modified immune epitopes.
According to them, antibodies elicited by modified self-
proteins tend to be promiscuous in their ability to bind ei-
ther the modified or the unmodified form of protein most
probably due to the contribution of conserved amino acids
flanking the modified residue. By contrast, T cell responses
are specific for the modified self-antigen with little or no
cross-reactivity with the unmodified self-antigen, as seen in
experimental autoimmune encephalomyelitis (EAE) and
multiple sclerosis, collagen-induced arthritis, celiac disease,
etc. (15, 49–52). For example, the acetylated NH2-terminal
peptide of myelin basic protein (MBP-Ac1–11) is required
for generating EAE, a murine model of human multiple
sclerosis. Nonacetylated peptide fails to stimulate T cells
and will not elicit EAE (53). In a similar manner, systemic
lupus erythematosus can be elicited in a murine model,
with an isoaspartyl-modified form of self-Ag (54). Re-
cently, it has been shown that in DR4-transgenic mice ex-
pressing human type II collagen, the rheumatoid arthritis
glycoprotein antigen, T cell responses to a “naked” peptide
epitope are strongly tolerized or even deleted, whereas T
cells specific for the corresponding glycosylated peptides
persist (55). While these observations have been made re-
garding the T cell specificity, very little is known about the
antigen processing pathways that give rise to these epitopes.
We were particularly interested in what happens to com-
plex oligosaccharides when glycoproteins are taken up,
processed, and presented to T cells by DCs. We have ad-
dressed processing and presentation of glycoprotein anti-
gens using as a model the tumor antigen MUC1 glycopep-
tides. As is the case with most antigens studied to date,
processing and presentation by DCs of unglycosylated
MUC1 peptides and their ability to elicit helper responses
has received considerable attention, while nothing is
known about how DCs handle glycosylated, synthetic or
native forms of MUC1 and what is the nature of the
epitopes presented to T cells.
We addressed important aspects of MUC1 processing by
DCs and assessed the impact of glycosylation on its presen-
tation to T cells using MHC class II–restricted T cell hybrid-
omas. Using peptide-specific clone VF5 we found that
DCs did not remove carbohydrates from glycopeptides that
were otherwise efficiently internalized and transported to
enzyme- and MHC class II–rich processing compartments.
It has been previously suggested that, if not removed, sug-
ars might prevent peptide binding to MHC class II or they
might interfere with TCR binding to the peptide–MHC
complex. Our results support the latter. Glycoepitopes
were generated even from the MUC1 Tn-100mer with at
least 15 monosaccharides attached to the peptide backbone,
however sugars attached to them prevented recognition by
VF5. To further support these observations we studied the
glycopeptide-specific VF9 hybridoma that requires the
presence of the disaccharide for the recognition of its
epitope and is not cross-reactive to the “naked” or
monosaccharide-substituted corresponding peptide.
Many of the in vitro glycosylated synthetic glycopeptides
used here display O-linked glycans like the Tn and T anti-
gens, found on cancer-associated MUC1. We have used
them as experimental tools to determine that saccharides
are not removed by DCs after endocytosis and that result-
Figure 7. VF5 and VF9 responses to tumor MUC1 glycoforms. DCs
were loaded for 16 h with antigen and coincubated with peptide-specific
VF5 (A) or VF9 hybridomas (B) for 24 h and supernatants tested for IL-2
presence by ELISA, as described above.1444 Carbohydrates Are Not Removed during Antigen Processing
ing MUC glycoepitopes are presented at the cell surface
generating glycopeptide-specific T cell responses. Yet the
in vivo glycosylation of MUC1 occurring in tumor cells is
an intricate biosynthetic process generating complex glyco-
sylation patterns that differ from normal cells and may vary
from one tumor cell type to another (23). MCF-7 and
T47D are two different breast cancer lines, which we used
as a source of secreted, in vivo glycosylated MUC1 glyco-
proteins. MUC1 derived from MCF-7 exhibits a substan-
tially lower glycosylation density compared with T47D,
and consequently a higher yield of “naked” MUC1
epitopes recognized by VF5. The relative incidence of T
tumor antigen among other sugars on MCF-7 MUC1 is
also higher than on T47D-derived MUC1, which resulted
in a more efficient generation of glycoepitopes recognized
by VF9.
In addition to class II–restricted epitopes, DCs that ac-
tively acquire exogenous antigens can generate MHC class
I–restricted peptides via both TAP-dependent and TAP-
independent pathway (56–59). Very little is currently
known about class I–restricted glycopeptides and it will be
equally important to determine if class I–restricted MUC1
glycoepitope-specific CD8  T cells can be generated.
While adenocarcinomas express very low levels of MHC
class II molecules and CD4  T cells are not expected to re-
act with tumor cells, CD8  T cells are expected to have a
direct antitumor effect. Understanding the intracellular fate
of glycosylated antigens taken up by DCs, and especially
those whose glycosylation is different between normal and
tumor cells, could have great impact on the design of can-
cer vaccines.
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